Despite the overwhelming success of vaccines in preventing infectious diseases, there
remain numerous globally devastating diseases without fully protective vaccines, particularly …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups.
Binding but non-neutralizing responses are directed to epitopes that are expressed on …

The development of native-like HIV-1 envelope (Env) trimer antigens has enabled the
induction of neutralizing antibody (NAb) responses against neutralization-resistant HIV-1 …

As the sole viral antigen on the HIV-1–virion surface, trimeric Env is a focus of vaccine
efforts. Here we present the structure of the ligand-free HIV-1–Env trimer, fix its conformation …

We describe the development and potential use of various designs of recombinant HIV‐1
envelope glycoprotein trimers that mimic the structure of the virion‐associated spike, which …

Despite numerous attempts over many years to develop an HIV vaccine based on classical
strategies, none has convincingly succeeded to date. A number of approaches are being …

As the sole target of broadly neutralizing antibodies (bnAbs) to HIV, the envelope
glycoprotein (Env) trimer is the focus of vaccination strategies designed to elicit protective …

A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The
high density and heterogeneity of the glycans shield Env from recognition by the immune …

The N-linked oligomannose glycans of HIV gp120 are a target for both microbicide and
vaccine design. The extent of cross-clade conservation of HIV oligomannose glycans is …